

Implanet announces its 2015 financial calendar

Bordeaux, Boston, December 22, 2014: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today its schedule for the publication of financial information for 2015.

| Event | Dates* |
|--------------------------|--------------------|
| 2014 Full-Year Sales | January 7, 2015 |
| 2014 Full-Year Results | March 31, 2015 |
| 2015 First-Quarter Sales | April 28, 2015 |
| Annual General Meeting | June 17, 2015 |
| 2015 First-Half Sales | July 28, 2015 |
| 2015 First-Half Results | September 15, 2015 |
| 2015 Third-Quarter Sales | October 27, 2015 |

Note (*): Press releases are published after market closes. Subject to modification.



About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris. Ticker: IMPL - ISIN code: FR0010458729





IMPLANET

Ludovic Lastennet

Tel.: +33 (0)5 57 99 55 55 investors@implanet.com

NewCap

Investor Relations Florent Alba Tel.: +33 (0)1 44 71 94 94 implanet@newcap.fr

NewCap

Press Relations Nicolas Merigeau Tel.: +33 (0)1 44 71 94 98 implanet@newcap.fr